{"id":126526,"date":"2026-09-06T08:02:34","date_gmt":"2026-09-06T08:02:34","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/126526\/"},"modified":"2026-09-06T08:02:34","modified_gmt":"2026-09-06T08:02:34","slug":"roche-nabs-simceres-preclinical-trispecific-tce-in-1-53b-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/126526\/","title":{"rendered":"Roche nabs Simcere\u2019s preclinical trispecific TCE in $1.53B deal"},"content":{"rendered":"<p>To read the full article <a href=\"https:\/\/www.bioworld.com\/user\/new\" rel=\"nofollow noopener\" target=\"_blank\">sign up for free<\/a> or <a href=\"https:\/\/www.bioworld.com\/user\/login\" rel=\"nofollow noopener\" target=\"_blank\">sign in<\/a>.<\/p>\n<p>Sep. 2, 2026<\/p>\n<p>  By <a href=\"https:\/\/www.bioworld.com\/authors\/603-marian-yoonjee-chu\" rel=\"nofollow noopener\" target=\"_blank\">Marian (YoonJee) Chu<\/a><\/p>\n<p>  <a title=\"Roche nabs Simcere\u2019s preclinical trispecific TCE in $1.53B deal \" class=\"more\" href=\"https:\/\/www.bioworld.com\/articles\/733762-roche-nabs-simceres-preclinical-trispecific-tce-in-153b-deal#comments-container\" rel=\"nofollow noopener\" target=\"_blank\">No Comments<\/a><\/p>\n<p>Roche Holding AG filled a trispecific antibody-sized hole in its B-cell disease franchise by bringing in Simcere Zaiming Pharmaceutical Co. Ltd.\u2019s SIM-0600, a preclinical CD79a\/CD19\/CD3-targeting trispecific T-cell engager (TCE), under a potential $1.53 billion license deal. <\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/84-bioworld\" rel=\"nofollow noopener\" target=\"_blank\">BioWorld<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/214-deals-and-m-a\" rel=\"nofollow noopener\" target=\"_blank\">Deals and M&amp;A<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/239-cancer\" rel=\"nofollow noopener\" target=\"_blank\">Cancer<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/250-immune\" rel=\"nofollow noopener\" target=\"_blank\">Immune<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/252-inflammatory\" rel=\"nofollow noopener\" target=\"_blank\">Inflammatory<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/268-antibody\" rel=\"nofollow noopener\" target=\"_blank\">Antibody<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/393-asia-pacific\" rel=\"nofollow noopener\" target=\"_blank\">Asia-Pacific<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/396-europe\" rel=\"nofollow noopener\" target=\"_blank\">Europe<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/395-china\" rel=\"nofollow noopener\" target=\"_blank\">China<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/401-u-s\" rel=\"nofollow noopener\" target=\"_blank\">U.S.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"To read the full article sign up for free or sign in. Sep. 2, 2026 By Marian (YoonJee)&hellip;\n","protected":false},"author":2,"featured_media":126527,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[1664,941,10486,61784,8086,2112,351,8568,197,929,15284,61006,7668,134,473,61782,61781,61780,44125,61783,2278],"class_list":["post-126526","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-antibody","tag-asia-pacific","tag-autoimmune-diseases","tag-b-cell-mediated-diseases","tag-bioworld","tag-cancer","tag-china","tag-deals-and-ma","tag-europe","tag-f-hoffmann-la-roche-ltd","tag-immune","tag-inflammatory","tag-lymphoma","tag-roche","tag-roche-holding-ag","tag-sim-0600","tag-simcere-pharmaceutical-group-ltd","tag-simcere-zaiming-pharmaceutical-co-ltd","tag-t-cell-engagers","tag-trispecific-t-cell-engagers","tag-u-s"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117223053202758017","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=126526"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126526\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/126527"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=126526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=126526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=126526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}